Phase 3 clinical trials of MDMA-assisted psychotherapy for post-traumatic stress disorder (PTSD) are currently underway in the USA, Canada, and Israel.

These trials, led by the Multidisciplinary Association for Psychedelic Studies (MAPS), are the last step in figuring out if this treatment is safe and effective enough for MDMA to be legally prescribed to treat PTSD.

If there’s a positive result from the trials, this could happen in the USA as soon as 2022.